Dr. Clifford A. Hudis on the Importance of In-Breast Response Rates in Triple-Negative Breast Cancer
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer. Huddis says that while carboplatin does not definitively produce long-term outcomes, the drug does improve in-breast response rate, which could be important in some cases. He adds that those cases would include inoperable breast cancer that medical professionals would be looking to convert into an operable case.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
